Financhill
Sell
19

APLS Quote, Financials, Valuation and Earnings

Last price:
$17.56
Seasonality move :
-4.83%
Day range:
$17.35 - $18.32
52-week range:
$16.65 - $43.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.86x
P/B ratio:
13.63x
Volume:
3M
Avg. volume:
3M
1-year change:
-57.9%
Market cap:
$2.2B
Revenue:
$781.4M
EPS (TTM):
-$1.79

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
APLS
Apellis Pharmaceuticals
$194.9M -$0.35 -6.47% -36.11% $39.76
ARDX
Ardelyx
$79.4M -$0.08 13.1% -94.66% $10.32
ARVN
Arvinas
$41.9M -$0.97 -54.66% -80.92% $22.36
MGNX
Macrogenics
$9.6M -$0.69 5.37% -17.86% $6.00
RYTM
Rhythm Pharmaceuticals
$40.2M -$0.68 48.98% -14.55% $82.08
YMAB
Y-mAbs Therapeutics
$19.6M -$0.20 -10.39% -10.89% $16.10
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
APLS
Apellis Pharmaceuticals
$17.81 $39.76 $2.2B -- $0.00 0% 2.86x
ARDX
Ardelyx
$3.64 $10.32 $870.9M -- $0.00 0% 2.38x
ARVN
Arvinas
$6.81 $22.36 $497.1M -- $0.00 0% 1.15x
MGNX
Macrogenics
$1.54 $6.00 $97.2M -- $0.00 0% 0.65x
RYTM
Rhythm Pharmaceuticals
$60.72 $82.08 $3.9B -- $0.00 0% 27.38x
YMAB
Y-mAbs Therapeutics
$4.04 $16.10 $182.9M -- $0.00 0% 2.04x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
APLS
Apellis Pharmaceuticals
73.41% 1.587 16.5% 3.38x
ARDX
Ardelyx
50.95% 1.385 12.88% 3.43x
ARVN
Arvinas
0.08% 3.030 0.1% 4.50x
MGNX
Macrogenics
-- -0.050 -- 3.71x
RYTM
Rhythm Pharmaceuticals
-- 1.841 -- 2.97x
YMAB
Y-mAbs Therapeutics
-- 0.488 -- 3.67x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
APLS
Apellis Pharmaceuticals
$132.4M -$83.3M -36.43% -96.34% -48.46% -$53.4M
ARDX
Ardelyx
$61.8M -$36.3M -19.51% -34.68% -45.91% -$38.8M
ARVN
Arvinas
-- $71.4M -7.71% -7.72% 37.82% -$89.3M
MGNX
Macrogenics
$12.2M -$52.8M -60.58% -60.58% -81.79% -$39M
RYTM
Rhythm Pharmaceuticals
$29.1M -$47M -116.92% -116.92% -134.57% -$40.4M
YMAB
Y-mAbs Therapeutics
$18.7M -$5.9M -30.91% -30.91% -22.4% -$1.9M

Apellis Pharmaceuticals vs. Competitors

  • Which has Higher Returns APLS or ARDX?

    Ardelyx has a net margin of -55.29% compared to Apellis Pharmaceuticals's net margin of -55.52%. Apellis Pharmaceuticals's return on equity of -96.34% beat Ardelyx's return on equity of -34.68%.

    Company Gross Margin Earnings Per Share Invested Capital
    APLS
    Apellis Pharmaceuticals
    79.4% -$0.74 $617.6M
    ARDX
    Ardelyx
    83.4% -$0.17 $297M
  • What do Analysts Say About APLS or ARDX?

    Apellis Pharmaceuticals has a consensus price target of $39.76, signalling upside risk potential of 123.26%. On the other hand Ardelyx has an analysts' consensus of $10.32 which suggests that it could grow by 183.47%. Given that Ardelyx has higher upside potential than Apellis Pharmaceuticals, analysts believe Ardelyx is more attractive than Apellis Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    APLS
    Apellis Pharmaceuticals
    12 8 0
    ARDX
    Ardelyx
    8 2 0
  • Is APLS or ARDX More Risky?

    Apellis Pharmaceuticals has a beta of 0.725, which suggesting that the stock is 27.458% less volatile than S&P 500. In comparison Ardelyx has a beta of 0.762, suggesting its less volatile than the S&P 500 by 23.846%.

  • Which is a Better Dividend Stock APLS or ARDX?

    Apellis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ardelyx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals pays -- of its earnings as a dividend. Ardelyx pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios APLS or ARDX?

    Apellis Pharmaceuticals quarterly revenues are $166.8M, which are larger than Ardelyx quarterly revenues of $74.1M. Apellis Pharmaceuticals's net income of -$92.2M is lower than Ardelyx's net income of -$41.1M. Notably, Apellis Pharmaceuticals's price-to-earnings ratio is -- while Ardelyx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals is 2.86x versus 2.38x for Ardelyx. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    APLS
    Apellis Pharmaceuticals
    2.86x -- $166.8M -$92.2M
    ARDX
    Ardelyx
    2.38x -- $74.1M -$41.1M
  • Which has Higher Returns APLS or ARVN?

    Arvinas has a net margin of -55.29% compared to Apellis Pharmaceuticals's net margin of 43.91%. Apellis Pharmaceuticals's return on equity of -96.34% beat Arvinas's return on equity of -7.72%.

    Company Gross Margin Earnings Per Share Invested Capital
    APLS
    Apellis Pharmaceuticals
    79.4% -$0.74 $617.6M
    ARVN
    Arvinas
    -- $1.14 $660.6M
  • What do Analysts Say About APLS or ARVN?

    Apellis Pharmaceuticals has a consensus price target of $39.76, signalling upside risk potential of 123.26%. On the other hand Arvinas has an analysts' consensus of $22.36 which suggests that it could grow by 228.36%. Given that Arvinas has higher upside potential than Apellis Pharmaceuticals, analysts believe Arvinas is more attractive than Apellis Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    APLS
    Apellis Pharmaceuticals
    12 8 0
    ARVN
    Arvinas
    9 8 0
  • Is APLS or ARVN More Risky?

    Apellis Pharmaceuticals has a beta of 0.725, which suggesting that the stock is 27.458% less volatile than S&P 500. In comparison Arvinas has a beta of 2.215, suggesting its more volatile than the S&P 500 by 121.499%.

  • Which is a Better Dividend Stock APLS or ARVN?

    Apellis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arvinas offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals pays -- of its earnings as a dividend. Arvinas pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios APLS or ARVN?

    Apellis Pharmaceuticals quarterly revenues are $166.8M, which are smaller than Arvinas quarterly revenues of $188.8M. Apellis Pharmaceuticals's net income of -$92.2M is lower than Arvinas's net income of $82.9M. Notably, Apellis Pharmaceuticals's price-to-earnings ratio is -- while Arvinas's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals is 2.86x versus 1.15x for Arvinas. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    APLS
    Apellis Pharmaceuticals
    2.86x -- $166.8M -$92.2M
    ARVN
    Arvinas
    1.15x -- $188.8M $82.9M
  • Which has Higher Returns APLS or MGNX?

    Macrogenics has a net margin of -55.29% compared to Apellis Pharmaceuticals's net margin of -86.98%. Apellis Pharmaceuticals's return on equity of -96.34% beat Macrogenics's return on equity of -60.58%.

    Company Gross Margin Earnings Per Share Invested Capital
    APLS
    Apellis Pharmaceuticals
    79.4% -$0.74 $617.6M
    MGNX
    Macrogenics
    69.04% -$0.25 $116.1M
  • What do Analysts Say About APLS or MGNX?

    Apellis Pharmaceuticals has a consensus price target of $39.76, signalling upside risk potential of 123.26%. On the other hand Macrogenics has an analysts' consensus of $6.00 which suggests that it could grow by 289.61%. Given that Macrogenics has higher upside potential than Apellis Pharmaceuticals, analysts believe Macrogenics is more attractive than Apellis Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    APLS
    Apellis Pharmaceuticals
    12 8 0
    MGNX
    Macrogenics
    2 5 0
  • Is APLS or MGNX More Risky?

    Apellis Pharmaceuticals has a beta of 0.725, which suggesting that the stock is 27.458% less volatile than S&P 500. In comparison Macrogenics has a beta of 2.201, suggesting its more volatile than the S&P 500 by 120.129%.

  • Which is a Better Dividend Stock APLS or MGNX?

    Apellis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Macrogenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals pays -- of its earnings as a dividend. Macrogenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios APLS or MGNX?

    Apellis Pharmaceuticals quarterly revenues are $166.8M, which are larger than Macrogenics quarterly revenues of $17.7M. Apellis Pharmaceuticals's net income of -$92.2M is lower than Macrogenics's net income of -$15.4M. Notably, Apellis Pharmaceuticals's price-to-earnings ratio is -- while Macrogenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals is 2.86x versus 0.65x for Macrogenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    APLS
    Apellis Pharmaceuticals
    2.86x -- $166.8M -$92.2M
    MGNX
    Macrogenics
    0.65x -- $17.7M -$15.4M
  • Which has Higher Returns APLS or RYTM?

    Rhythm Pharmaceuticals has a net margin of -55.29% compared to Apellis Pharmaceuticals's net margin of -151.35%. Apellis Pharmaceuticals's return on equity of -96.34% beat Rhythm Pharmaceuticals's return on equity of -116.92%.

    Company Gross Margin Earnings Per Share Invested Capital
    APLS
    Apellis Pharmaceuticals
    79.4% -$0.74 $617.6M
    RYTM
    Rhythm Pharmaceuticals
    88.85% -$0.81 $163.1M
  • What do Analysts Say About APLS or RYTM?

    Apellis Pharmaceuticals has a consensus price target of $39.76, signalling upside risk potential of 123.26%. On the other hand Rhythm Pharmaceuticals has an analysts' consensus of $82.08 which suggests that it could grow by 31.62%. Given that Apellis Pharmaceuticals has higher upside potential than Rhythm Pharmaceuticals, analysts believe Apellis Pharmaceuticals is more attractive than Rhythm Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    APLS
    Apellis Pharmaceuticals
    12 8 0
    RYTM
    Rhythm Pharmaceuticals
    8 0 0
  • Is APLS or RYTM More Risky?

    Apellis Pharmaceuticals has a beta of 0.725, which suggesting that the stock is 27.458% less volatile than S&P 500. In comparison Rhythm Pharmaceuticals has a beta of 2.362, suggesting its more volatile than the S&P 500 by 136.233%.

  • Which is a Better Dividend Stock APLS or RYTM?

    Apellis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals pays -- of its earnings as a dividend. Rhythm Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios APLS or RYTM?

    Apellis Pharmaceuticals quarterly revenues are $166.8M, which are larger than Rhythm Pharmaceuticals quarterly revenues of $32.7M. Apellis Pharmaceuticals's net income of -$92.2M is lower than Rhythm Pharmaceuticals's net income of -$49.5M. Notably, Apellis Pharmaceuticals's price-to-earnings ratio is -- while Rhythm Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals is 2.86x versus 27.38x for Rhythm Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    APLS
    Apellis Pharmaceuticals
    2.86x -- $166.8M -$92.2M
    RYTM
    Rhythm Pharmaceuticals
    27.38x -- $32.7M -$49.5M
  • Which has Higher Returns APLS or YMAB?

    Y-mAbs Therapeutics has a net margin of -55.29% compared to Apellis Pharmaceuticals's net margin of -25.63%. Apellis Pharmaceuticals's return on equity of -96.34% beat Y-mAbs Therapeutics's return on equity of -30.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    APLS
    Apellis Pharmaceuticals
    79.4% -$0.74 $617.6M
    YMAB
    Y-mAbs Therapeutics
    70.4% -$0.15 $92M
  • What do Analysts Say About APLS or YMAB?

    Apellis Pharmaceuticals has a consensus price target of $39.76, signalling upside risk potential of 123.26%. On the other hand Y-mAbs Therapeutics has an analysts' consensus of $16.10 which suggests that it could grow by 298.52%. Given that Y-mAbs Therapeutics has higher upside potential than Apellis Pharmaceuticals, analysts believe Y-mAbs Therapeutics is more attractive than Apellis Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    APLS
    Apellis Pharmaceuticals
    12 8 0
    YMAB
    Y-mAbs Therapeutics
    7 0 1
  • Is APLS or YMAB More Risky?

    Apellis Pharmaceuticals has a beta of 0.725, which suggesting that the stock is 27.458% less volatile than S&P 500. In comparison Y-mAbs Therapeutics has a beta of 0.531, suggesting its less volatile than the S&P 500 by 46.863%.

  • Which is a Better Dividend Stock APLS or YMAB?

    Apellis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Y-mAbs Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals pays -- of its earnings as a dividend. Y-mAbs Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios APLS or YMAB?

    Apellis Pharmaceuticals quarterly revenues are $166.8M, which are larger than Y-mAbs Therapeutics quarterly revenues of $26.5M. Apellis Pharmaceuticals's net income of -$92.2M is lower than Y-mAbs Therapeutics's net income of -$6.8M. Notably, Apellis Pharmaceuticals's price-to-earnings ratio is -- while Y-mAbs Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals is 2.86x versus 2.04x for Y-mAbs Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    APLS
    Apellis Pharmaceuticals
    2.86x -- $166.8M -$92.2M
    YMAB
    Y-mAbs Therapeutics
    2.04x -- $26.5M -$6.8M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Is a Millionaire-Maker Stock?
What Is a Millionaire-Maker Stock?

From time to time, investors will run across the term…

5 Investors to Follow Other Than Warren Buffett
5 Investors to Follow Other Than Warren Buffett

There is no doubt that Warren Buffett is one of…

Is BYD a Threat To Tesla Shareholders?
Is BYD a Threat To Tesla Shareholders?

BYD (OTC:BYDDY) has rocketed to the top of China’s booming…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Buy
63
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 40x

Alerts

Buy
99
DAVE alert for May 9

Dave [DAVE] is up 7.34% over the past day.

Buy
52
QDEL alert for May 9

QuidelOrtho [QDEL] is down 0.82% over the past day.

Buy
61
TPC alert for May 9

Tutor Perini [TPC] is up 7.53% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock